Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antidepressant + bupropion SR
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This treatment strategy involves the augmentation of a primary antidepressant (typically a selective serotonin reuptake inhibitor [SSRI], serotonin-norepinephrine reuptake inhibitor [SNRI], or mirtazapine) with bupropion sustained-release (SR). Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that acts by inhibiting the neuronal reuptake of norepinephrine and dopamine. This combination is used to improve outcomes in patients with major depressive disorder (MDD) who have not achieved an adequate response to initial monotherapy. The strategy was a key arm in the VAST-D (VA Augmentation and Switching Treatments for Improving Depression Outcomes) trial, sponsored by the VA Office of Research and Development, which compared augmentation strategies to switching monotherapies in veterans.
- Brand names
- Wellbutrin SR
- Other names
- bupropion SR augmentationSSRI + bupropion SRSNRI + bupropion SRmirtazapine + bupropion SR
02
Targets
SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)Nicotinic Acetylcholine Receptor
Beyond the preview
Go deeper on antidepressant + bupropion SR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antidepressant + bupropion SR.